11β-HSD1抑制剂S-707106治疗库欣综合征及自主皮质醇分泌的开放标签I/IIa期临床试验
主要终点(24周时75g OGTT血糖AUC降低25%的应答者比例)未达到,但12周时血糖AUC显著降低,体脂百分比下降、体肌肉百分比上升。
要点
- S-707106未达到主要终点(应答者比例>20%)。
- 12周时血糖AUC显著降低7.1%,24周时降低2.7%但无统计学意义。
- 体脂百分比下降2.5%,体肌肉百分比上升2.4%。
核心结论
- S-707106是这些患者的有效胰岛素增敏剂、抗肌肉减少和抗肥胖药物。
主要发现
- 24周时未达到主要终点(应答者比例>20%)。
- 12周时血糖AUC降低-7.1%[SD 14.8(90%CI -14.8至-1.0),P=0.033],24周时降低-2.7%[14.5(-10.2至3.4),P=0.18]。
- 高体重指数患者血糖AUC显著降低。
- 体脂百分比下降-2.5%[1.7(-3.3至-1.8),P<0.001],体肌肉百分比上升2.4%[1.6(1.7至3.1),P<0.001]。
关键数值与推荐
- 主要终点应答定义为24周时75g口服葡萄糖耐量试验中血浆葡萄糖AUC降低25%。
- 12周时口服葡萄糖耐量试验结果改善不足者,后12周剂量增至200 mg每日两次。
临床怎么用
- S-707106可作为库欣综合征及自主皮质醇分泌患者的胰岛素增敏、抗肌肉减少和抗肥胖治疗选择。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
CONTEXT: 11β-hydroxysteroid dehydrogenase type 1 (11β-HSD1) inhibitors demonstrate antimetabolic and antisarcopenic effects in Cushing's syndrome (CS) and autonomous cortisol secretion (ACS) patients. OBJECTIVE: To confirm the efficacy and safety of S-707106 (11β-HSD1 inhibitor) administered to CS and ACS patients. DESIGN: A 24-week single-center, open-label, single-arm, dose-escalation, investigator-initiated clinical trial on a database. SETTING: Kyushu University Hospital, Kurume University Hospital, and related facilities. PATIENTS: Sixteen patients with inoperable or recurrent CS and ACS, with mildly impaired glucose tolerance. INTERVENTION: Oral administration of 200 mg S-707106 after dinner, daily, for 24 weeks. In patients with insufficient improvement in oral glucose tolerance test results at 12 weeks, an escalated dose of S-707106 (200 mg twice daily) was administered for the residual 12 weeks. MAIN OUTCOME MEASURES: The rate of participants responding to glucose tolerance impairment, defined as those showing a 25% reduction in the area under the curve (AUC) of plasma glucose during the 75-g oral glucose tolerance test at 24 weeks. RESULTS: S-707106 administration could not achieve the primary endpoint of this clinical trial (>20% of responsive participants). AUC glucose decreased by -7.1% [SD, 14.8 (90% CI -14.8 to -1.0), P = 0.033] and -2.7% [14.5 (-10.2 to 3.4), P = 0.18] at 12 and 24 weeks, respectively. S-707106 administration decreased AUC glucose significantly in participants with a high body mass index. Body fat percentage decreased by -2.5% [1.7 (-3.3 to -1.8), P < 0.001] and body muscle percentage increased by 2.4% [1.6 (1.7 to 3.1), P < 0.001]. CONCLUSIONS: S-707106 is an effective insulin sensitizer and antisarcopenic and antiobesity medication for these patients.
引用
- Oda S, Ashida K, Uchiyama M, et al. An Open-label Phase I/IIa Clinical Trial of 11β-HSD1 Inhibitor for Cushing's Syndrome and Autonomous Cortisol Secretion. J Clin Endocrinol Metab. 2021. PMID: 34143883. doi:10.1210/clinem/dgab450
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。